Replies to post #32496 on Biotech Values

[mskatiescarletohara]

ANDS CC was that NVS did not opt to license ANA380 during the period of contractual exclusivity.

I didn't pick up on that, must have stepped out of the room when it appeared the CC was more focused on other agents in the pipeline.

Toll receptors may not be something NVS wants to pursue afterall.

katie...